江苏龙网

  1. 首页 > 生活 > >

肺癌|为何肺癌可以治愈，却多数耽误，全因肺癌这一特点！( 二 )


总之 ， 肺癌治愈的关键在于早期诊断和早期治疗 。 低剂量螺旋 CT 筛查可以提高早期诊断率 ， 通过手术切除治愈早期肺癌 。 病理学类型、诊断分期、分子类型、患者身心状态和依从性等 ， 都是影响生活时间的关键因素 。 肺癌并非绝症 ， 随着“精准医学”的不断发展 ， 科学规范的治疗也能给晚期患者带来新希望 。
肺癌|为何肺癌可以治愈，却多数耽误，全因肺癌这一特点！
本文插图
参考文献
[1]Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS.Survival of patients with stage I lung cancer detected on CT screening[J].N Engl J Med,2006,355(17):1763-71.
[2]葛均波、徐永健.内科学-第8版[M].人民卫生出版社.
[3]Scagliotti, G.V., et al.Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol, 2008. 26(21): p. 3543-51.
[4]Detterbeck, F.C., et al.The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification[J].J Thorac Oncol, 2016. 11(5): p. 639-50.
[5]Mok, T.S., et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):p.947-57.
[6]Fukuoka, M., et al.Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J].J Clin Oncol,2011,29(21): p.2866-74.
[7]Han, J.Y., et al.First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J].J Clin Oncol,2012,30(10): p.1122-8.
[8]Wu, Y.L., et al.First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study[J].Ann Oncol,2015,26(9): p.1883-9.
[9]Lee, C.K., et al.Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival[J].J Natl Cancer Inst, 2017.109(6).
[10]Soria, J.C., et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J].N Engl J Med, 2018. 378(2): p. 113-125..
[11]Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death[EB/OL].https://www.roche.com/media/releases/med-cor-2018-05-17b.htm.
[12]Gettinger, S., et al..Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.[J].J Clin Oncol, 2018: p. JCO2017770412..
*本文内容为健康知识科普 ， 不能作为具体的诊疗建议使用 ， 亦不能替代执业医师面诊 ， 仅供参考 。
*本文版权归腾讯医典所有 ， 未经授权禁止媒体转载 ， 违规转载将依法追究法律责任 。 欢迎个人转发至朋友圈 。


推荐阅读


上一篇：医联媒体|尿酸高先别慌，谨记“离2物，做3事”，尿酸或会悄悄降

下一篇：山大二院肿瘤科|指甲油致癌物质超标1400多倍，常涂指甲油真的会致癌吗？